Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 3Chemotherapy Induced Neutropenia 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Hodgkin Disease 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 216Methotrexate 140Cytarabine 131Vincristine 110fludarabine phosphate 103Peripheral Blood Stem Cell Transplantation 98Filgrastim 92Etoposide 92Dexamethasone 89Mycophenolic Acid 71Doxorubicin 70Whole-Body Irradiation 67Mercaptopurine 66Busulfan 65Tacrolimus 64Radiotherapy 63Cyclosporine 62Prednisone 55Daunorubicin 53pegaspargase 51Asparaginase 51Rituximab 48fludarabine 47Granulocyte Colony-Stimulating Factor 46Melphalan 45Antilymphocyte Serum 43Clofarabine 42Calcium Dobesilate 38Methylprednisolone 36Leucovorin 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Precursor Cell Lymphoblastic Leukemia-Lymphoma × pegylated granulocyte colony-stimulating factor, human × Clear all
NCT00671658 2020-12-03

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
220 enrolled 6 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡